Exclusive responsibility for preparing the Agency's opinions on all questions concerning medicinal products for human use should be vested in a Committee for Medicinal Products for Human Use. As far as veterinary medicinal products are concerned, such responsibility should be vested in a Committee for Medicinal Products for Veterinary Use. As regards orphan medicinal products, the task should fall to the Committee on Orphan Medicinal Products set up under Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products(11). Lastly, as regards herbal medicinal products, this responsibility should be vested in the Committee on Herbal Medicinal Products set up under Directive 2001/83/EC.
Recital 23, Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…
Judgment of the General Court (Sixth Chamber) of 19 December 2019. Vanda Pharmaceuticals Ltd v European Commission.Decision
Since, as stated in recital 23 of Regulation No 726/2004, ‘exclusive responsibility for preparing the [EMA]’s opinions on all questions concerning medicinal products for human use should be vested in a Committee for Medicinal Products …
19 Dec 2019 · 62018TJ0211
Arrêt du Tribunal (huitième chambre) du 2 mars 2022. Debregeas et associés Pharma (D & A Pharma) contre Commission européenne et Agence euroDecision
S’agissant de l’avis de l’EMA, il résulte du considérant 23 et de l’article 5, paragraphe 2, du règlement n o 726/2004 que la « responsabilité exclusive » de sa préparation est confiée au CHMP, institué par l’article 121 …
2 Mar 2022 · 62020TJ0556
Judgment of the Court (Fourth Chamber) of 14 March 2024. Debregeas et associés Pharma (D & A Pharma) v European Commission and European MediDecision
Recitals 19 and 23 of Regulation No 726/2004 state: The chief task of the [European Medicines Agency (EMA)] should be to provide [European Union] institutions and Member States with the best possible scientific opinions so as to enable …
14 Mar 2024 · 62022CJ0291
Judgment of the General Court (Sixth Chamber) of 28 October 2020. Pharma Mar, SA v European Commission.Decision
As regards the EMA’s opinion, it is clear from recital 23 and Article 5(2) of Regulation No 726/2004 that ‘exclusive responsibility’ for preparing it is conferred on the CHMP.
28 Oct 2020 · 62018TJ0594
Judgment of the General Court (Fifth Chamber, Extended Composition) of 24 September 2025. Sanofi BV, anciennement Genzyme Europe BV v EuropeDecision
Second, in accordance with recital 23 and Article 5(2), Article 56(1)(a) and Article 61(7) of Regulation No 726/2004, the ‘exclusive responsibility’ for the preparation of the EMA’s opinions on all questions concerning medicinal …
24 Sep 2025 · 62022TJ0483
Opinion of Advocate General Medina delivered on 7 September 2023. Debregeas et associés Pharma (D & A Pharma) v European Commission and EuroDecision
As regards the EMA’s opinion, it follows from Article 5(2) of Regulation No 726/2004, read in the light of recital 23 of that regulation, that ‘exclusive responsibility’ for its preparation is vested in the CHMP, established by …
7 Sep 2023 · 62022CC0291